BR112014025081A2 - Metabólito de colesterol, 5-colesten, 3beta- 25- diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças hepáticas gordurosas e aterosclerose - Google Patents

Metabólito de colesterol, 5-colesten, 3beta- 25- diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças hepáticas gordurosas e aterosclerose

Info

Publication number
BR112014025081A2
BR112014025081A2 BR112014025081-2A BR112014025081A BR112014025081A2 BR 112014025081 A2 BR112014025081 A2 BR 112014025081A2 BR 112014025081 A BR112014025081 A BR 112014025081A BR 112014025081 A2 BR112014025081 A2 BR 112014025081A2
Authority
BR
Brazil
Prior art keywords
25hcds
diol
3beta
hyperlipidemia
diabetes
Prior art date
Application number
BR112014025081-2A
Other languages
English (en)
Other versions
BR112014025081B1 (pt
Inventor
Ren Shunlin
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of BR112014025081A2 publication Critical patent/BR112014025081A2/pt
Publication of BR112014025081B1 publication Critical patent/BR112014025081B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "metabólito de colesterol, 5-colesten, 3beta-25-diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças hepáticas gordurosas e aterosclerose". a presente invenção refere-se a 5-colesten, 3ß, 25-diol, dissulfato (25hcds) que constatou-se ser agonista ppar? autêntico e antagonista de lxr, e é usado para terapia de distúrbios de lipídio e doenças inflamatórias, incluindo, sem limitação, hepáticas gordurosas, doenças inflamatórias, e doenças ateroscleróticas.
BR112014025081-2A 2012-04-12 2013-03-15 metabólito de colesterol, 5-colesten-3,25-diol, dissulfato (25hcds), seu uso, composições compreendendo o mesmo, bem como processos de produção do referido composto e da referida composição BR112014025081B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261623203P 2012-04-12 2012-04-12
US201261623414P 2012-04-12 2012-04-12
US61/623,414 2012-04-12
US61/623,203 2012-04-12
PCT/US2013/031861 WO2013154752A1 (en) 2012-04-12 2013-03-15 A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS

Publications (2)

Publication Number Publication Date
BR112014025081A2 true BR112014025081A2 (pt) 2018-05-08
BR112014025081B1 BR112014025081B1 (pt) 2020-12-08

Family

ID=49328028

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025081-2A BR112014025081B1 (pt) 2012-04-12 2013-03-15 metabólito de colesterol, 5-colesten-3,25-diol, dissulfato (25hcds), seu uso, composições compreendendo o mesmo, bem como processos de produção do referido composto e da referida composição

Country Status (21)

Country Link
US (6) US20150072962A1 (pt)
EP (2) EP3239163A1 (pt)
JP (4) JP6125610B2 (pt)
KR (1) KR102180485B1 (pt)
CN (2) CN104220450B (pt)
AU (2) AU2013246435B2 (pt)
BR (1) BR112014025081B1 (pt)
CA (1) CA2867694C (pt)
DK (1) DK2836502T3 (pt)
EA (1) EA026683B1 (pt)
ES (1) ES2641841T3 (pt)
HK (1) HK1202294A1 (pt)
HU (1) HUE035073T2 (pt)
IL (1) IL234892B (pt)
IN (1) IN2014KN02366A (pt)
MX (1) MX357046B (pt)
PL (1) PL2836502T3 (pt)
PT (1) PT2836502T (pt)
SI (1) SI2836502T1 (pt)
WO (1) WO2013154752A1 (pt)
ZA (1) ZA201406981B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EP3239163A1 (en) * 2012-04-12 2017-11-01 Virginia Commonwealth University A novel cholesterol metabolite, 5-cholesten-3,25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis
US10272097B2 (en) * 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
EA034524B1 (ru) * 2014-10-10 2020-02-17 Вирджиния Коммонвелт Юниверсити Сульфаты окисленного холестерина для лечения пониженной лептиновой активности
WO2016103722A1 (en) * 2014-12-24 2016-06-30 Kyoto University Vitamin d3 derivatives and pharmaceutical use thereof
AU2017306140A1 (en) * 2016-08-02 2019-02-21 Durect Corporation Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions
WO2018026837A1 (en) * 2016-08-02 2018-02-08 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
SI3494125T1 (sl) 2016-08-02 2022-10-28 Virginia Commonwealth University Sestavki, ki vsebujejo 5-holesten-3, 25-diol, 3-sulfat(25HC3S) ali njegovo farmacevtsko sprejemljivo sol in vsaj en cikličen oligosaharid
US11458146B2 (en) 2017-01-13 2022-10-04 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR101892577B1 (ko) 2017-04-21 2018-08-28 부산대학교 산학협력단 레블라스타틴 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 조성물
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
WO2019043700A1 (en) * 2017-08-31 2019-03-07 Ariel Scientific Innovations Ltd S. SPINOSUM EXTRACT FOR THE TREATMENT OF HEPATIC STEATOSIS
EP4037650A4 (en) * 2019-09-30 2023-10-18 Durect Corporation TREATMENT OF ALCOHOLIC HEPATITIS
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
KR20230061860A (ko) 2021-10-29 2023-05-09 부산대학교 산학협력단 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물
WO2024008614A1 (en) * 2022-07-08 2024-01-11 Société des Produits Nestlé S.A. Use of 25-hydroxycholesterol for diabetic treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020028876A (ko) * 1999-04-30 2002-04-17 추후제출 스테로이드 유도체
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
EP1983972A4 (en) 2006-02-13 2012-01-25 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
EP3239163A1 (en) * 2012-04-12 2017-11-01 Virginia Commonwealth University A novel cholesterol metabolite, 5-cholesten-3,25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis

Also Published As

Publication number Publication date
AU2017268646B2 (en) 2019-07-11
WO2013154752A1 (en) 2013-10-17
US20180127457A1 (en) 2018-05-10
US20200157140A1 (en) 2020-05-21
HK1202294A1 (en) 2015-09-25
MX2014012324A (es) 2015-05-11
EA026683B1 (ru) 2017-05-31
JP2021138713A (ja) 2021-09-16
US20190135856A1 (en) 2019-05-09
AU2013246435A1 (en) 2014-10-16
CN104220450A (zh) 2014-12-17
JP2019089777A (ja) 2019-06-13
US20150072962A1 (en) 2015-03-12
AU2013246435B2 (en) 2017-10-05
CN104220450B (zh) 2016-07-06
CA2867694C (en) 2021-08-31
EP2836502B1 (en) 2017-08-02
PL2836502T3 (pl) 2018-01-31
HUE035073T2 (en) 2018-05-02
MX357046B (es) 2018-06-22
CN106083976B (zh) 2018-02-09
CN106083976A (zh) 2016-11-09
CA2867694A1 (en) 2013-10-17
DK2836502T3 (en) 2017-10-23
EP2836502A1 (en) 2015-02-18
JP6125610B2 (ja) 2017-05-10
KR20150013520A (ko) 2015-02-05
AU2017268646A1 (en) 2017-12-21
IL234892B (en) 2019-02-28
US20210238219A1 (en) 2021-08-05
EP2836502A4 (en) 2015-08-19
PT2836502T (pt) 2017-10-27
US20160355544A1 (en) 2016-12-08
ES2641841T3 (es) 2017-11-14
ZA201406981B (en) 2016-05-25
IN2014KN02366A (pt) 2015-05-01
EA201491859A1 (ru) 2015-02-27
JP2017160213A (ja) 2017-09-14
BR112014025081B1 (pt) 2020-12-08
SI2836502T1 (sl) 2017-11-30
KR102180485B1 (ko) 2020-11-18
EP3239163A1 (en) 2017-11-01
JP2015512937A (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
BR112014025081A2 (pt) Metabólito de colesterol, 5-colesten, 3beta- 25- diol, dissulfato (25hcds) para terapia de distúrbios metabólicos, hiperlipidemia, diabetes, doenças hepáticas gordurosas e aterosclerose
FR23C1022I2 (fr) Inhibiteurs du recyclage de l'acide biliaire pour traitement de maladies cholestatiques hepatiques pediatriques
BRPI0819690A2 (pt) Método para tratar um paciente que sofre de doença do fígado gorduroso
BR112013030152A2 (pt) método implantado por computador que habilita um formato de apresentação para um bloco de aplicativo
BR112013022712A2 (pt) sistema e método de formar produto de confeitaria de múltiplas camadas
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
FR2980963B1 (fr) Amelioration aux appareils refrigeres d'exposition de produits
DK2701695T3 (da) Neurodegenerative lidelser og muskelsygdomme, der involverer polyumættede fedtsyrer
CL2014000995A1 (es) Composicion de prodroga que comprende un conjugado de hidromorfona y un acido arilcarboxilico; un método para tratar un paciente que comprende la administracion de la composicion.
BR112015026513A2 (pt) derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
BR112018012590A2 (pt) formas cristalinas polimórficas do ácido obeticólico
CR20140554A (es) Compuestos de acido dimetil-benzoico
CL2013001604A1 (es) Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
IL233639A0 (en) Preparations and methods for the treatment of diseases and liver disorders
BR112015003561A2 (pt) retinoides e sua utilização
BR112013031795A2 (pt) método para tratar uma doença
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013021620A2 (pt) métodos, aparelhos e sistemas para calcular uma quantia a ser cobrada em relação à execução de uma publicidade out-of-home durante um período de tempo
IL235000B (en) Preparations for oral administration and their use for the treatment of motor disorders
BR112013030145A2 (pt) processo para preparação de ácido metacrílico
FR2981572B1 (fr) Compositions pharmaceutiques d'acide ursodesoxycholique
MX2015007082A (es) Métodos de administración de composiciones que comprenden ácido docosapentanoico.
BR112013014307A2 (pt) compostos que influenciam na captação e metabolismo de ácidos graxos e na produção de agentes inflamatórios e métodos de isolamento dos mesmos de produtos de cacau
CO6801771A2 (es) Composición oral que comprende sodio divalproexy proceso para preparar la misma
FR2989272B1 (fr) Composition procurant une sensation de refroidissement et utilisation d'un ester de sterol

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2766 DE 09-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.